HRAS and neoplasm: With the caveat that the KPPC background may be so aggressive as to mask any effect on early tumorigenesis caused by the loss of Hras, these data are consistent with a model whereby a homozygous mutant p53 background can negate the tumor-suppressive effects of wild-type Hras on both pancreatic tumorigenesis and survival.